Physician profile
Howard Quint
NPI 1497984850
$3,070.20
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $849 · 2021: $760 · 2022: $140 · 2024: $47.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $47.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $47.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $607.63 | 2019-2022 | |
| Lilly USA, LLC | $252.43 | 2019-2021 | |
| Pfizer INC. | $248.48 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $179.59 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $174.63 | 2021 | |
| Zyla Life Sciences, INC. | $163.99 | 2020 | |
| Horizon Therapeutics Plc | $154.76 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $140.90 | 2019-2022 | |
| Sentynl Therapeutics, INC. | $139.33 | 2019 | |
| Arbor Pharmaceuticals, INC. | $120.66 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $119.05 | 2019-2020 | |
| Assertio Therapeutics, INC. | $115.50 | 2019-2020 | |
| Amgen INC. | $74.95 | 2019-2020 | |
| Allergan, INC. | $66.06 | 2020 | |
| Vertical Pharmaceuticals, LLC | $60.56 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $57.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.33 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.96 | 2022 | |
| Virtus Pharmaceuticals LLC | $47.15 | 2024 | Levorphanol Tartrate |
| Kaleo, INC. | $46.52 | 2019 | |
| Indivior INC. | $37.94 | 2019 | |
| Orexo US, INC. | $30.91 | 2020 | |
| Stimwave Technologies Incorporated | $24.83 | 2019 | |
| Biodelivery Sciences International, INC. | $23.91 | 2019 | |
| Grt US Holding, INC. | $22.86 | 2019 | |
| Gilead Sciences, INC. | $21.09 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Neuronetics, INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Quint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.